Report: Psoriatic arthritis market to reach $12.6bn by 2025


The psoriatic arthritis market is projected to grow from $4.53bn in 2015 to approximately $12.6bn by 2025 in the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK and Japan, according to a report by GlobalData.

Titled 'PharmaPoint: Psoriatic Arthritis – Global Drug Forecast and Market Analysis to 2025', the report forecasts the psoriatic arthritis market to witness a compound annual growth rate of 10.74%.

An increased awareness of the disease and development of interleukin (IL)-17 inhibitors and are expected to be the major drivers of growth. Educational campaigns and an interdisciplinary approach to managing the condition have increased awareness of the disease.

As a result, the total number of treated cases in the 7MM is expected to increase from roughly 770,000 in 2015 to 1.2 million by 2025, according to GlobalData immunology analyst Alexandra Annis, MS.

"An increased awareness of the disease and development of interleukin (IL)-17 inhibitors and are expected to be the major drivers of growth."

Existing treatment options do not have long-term efficacy requiring patients to have a cycle through the drugs. New therapeutic options with strong clinical efficacy will provide patients and physicians with more choice.

The recent approval of Novartis’ IL-17 inhibitor Cosentyx has been welcomed by the psoriatic arthritis community. The drug shows the highest clinical efficacy of any biologic approved with X-ray assessment data demonstrating 84% of patients as showing no progression in structural joint damage over a period of two years of use.

The psoriatic arthritis market is expected to have a range of therapeutic options over the forecast period, including Eli Lilly’s Taltz (ixekizumab), AstraZeneca’s Lumicef (brodalumab) and Celgene’s oral therapy Otezla (apremilast).

Lumicef and Taltz are expected to emerge as the leading drugs in the market, with the latter expected to gross an estimated $1.42bn in total sales by 2025. New entrants, however, are expected to face difficulties in terms of increased choice and reduced drug costs.